Nasus Pharma Ltd APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Nasus Pharma Ltd (NSRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $447.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-03-25
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|
| 2025-12-31 | $447.00K 20-F · filed 2026-03-25 | |
| 2025-06-30 | $150.00K 6-K · filed 2025-12-29 | |
| 2024-12-31 | $10.00K 20-F · filed 2026-03-25 | |
| 2024-06-30 | $5.00K 6-K · filed 2025-12-29 | |
| 2023-12-31 | $39.00K 20-F · filed 2026-03-25 |